REDWOOD
CITY, Calif., Nov. 15,
2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a
global medical device company that is delivering comprehensive,
life-changing solutions for the treatment of chronic pain,
announced that on November 7, 2024,
the Compensation Committee of the Company's Board of Directors
granted inducement restricted stock unit awards covering 37,726
shares of Nevro's common stock to 24 new non-executive employees to
induce them to accept employment with Nevro. Each award was granted
under the Nevro Corp. 2023 Inducement Award Plan and vests over a
three-year period, subject to continued employment with Nevro
through each vesting date.
Each award was granted as a material inducement to employment in
accordance with the NYSE Listed Company Manual Rule 303A.08.
Internet Posting of Information
Nevro routinely posts information that may be important to
investors in the "Investor Relations" section of its website at
www.nevro.com. The company encourages investors and potential
investors to consult the Nevro website regularly for important
information about Nevro.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on delivering comprehensive, life-changing solutions that continue
to set the standard for enduring patient outcomes in chronic pain
treatment. The company started with a simple mission to help more
patients suffering from debilitating pain and developed its
proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic
innovation that has impacted the lives of more than 100,000
patients globally. Nevro's comprehensive HFX™ spinal cord
stimulation (SCS) platform includes a Senza SCS system and support
services for the treatment of chronic pain of the trunk and limb
and painful diabetic neuropathy.
Senza®, Senza II®, Senza Omnia™, and HFX iQ are the
only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.
Nevro's unique support services provide every patient with an HFX
Coach™ throughout their pain relief journey and every physician
with Nevrocloud™ insights for enhanced patient and practice
management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, Nevrocloud, RELIEF MULTIPLIED,
HFX AdaptivAI, the X logo, NEVRO, and the NEVRO logo are trademarks
or registered trademarks of Nevro Corp. Patents covering Senza HFX
iQ and other Nevro products are listed at Nevro.com/patents.
Bluetooth® and the Bluetooth symbol are registered
trademarks of their respective owners.
To learn more about Nevro, connect with us on LinkedIn, X,
Facebook, and Instagram.
Investor and Media Contact:
Angie McCabe
Vice President, Investor Relations & Corporate
Communications
angeline.mccabe@nevro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-announces-new-employee-inducement-grants-under-nyse-rule-303a08-302306326.html
SOURCE Nevro Corp.